Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Sells $31,424.40 in Stock

Aadi Bioscience, Inc. (NASDAQ:AADIGet Free Report) Chairman Neil Desai sold 14,964 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $2.10, for a total transaction of $31,424.40. Following the completion of the sale, the chairman now owns 1,411,543 shares of the company’s stock, valued at $2,964,240.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Neil Desai also recently made the following trade(s):

  • On Friday, March 1st, Neil Desai sold 27,036 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.97, for a total transaction of $53,260.92.
  • On Thursday, February 1st, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.74, for a total transaction of $73,080.00.
  • On Tuesday, January 2nd, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The stock was sold at an average price of $2.06, for a total transaction of $86,520.00.
  • On Wednesday, December 6th, Neil Desai sold 7,037 shares of Aadi Bioscience stock. The stock was sold at an average price of $4.82, for a total transaction of $33,918.34.

Aadi Bioscience Trading Up 26.8 %

NASDAQ:AADI traded up $0.52 during trading hours on Monday, reaching $2.44. The company had a trading volume of 3,812,571 shares, compared to its average volume of 434,343. Aadi Bioscience, Inc. has a 52 week low of $1.55 and a 52 week high of $9.41. The firm has a market cap of $59.73 million, a price-to-earnings ratio of -1.03 and a beta of 0.57. The firm’s 50 day moving average price is $1.85 and its 200-day moving average price is $3.76.

Analysts Set New Price Targets

AADI has been the subject of several recent research reports. HC Wainwright lowered shares of Aadi Bioscience from a “buy” rating to a “neutral” rating in a report on Friday, December 15th. Piper Sandler lowered their target price on shares of Aadi Bioscience from $30.00 to $5.00 and set an “overweight” rating for the company in a report on Friday, December 15th.

View Our Latest Analysis on Aadi Bioscience

Institutional Investors Weigh In On Aadi Bioscience

A number of large investors have recently added to or reduced their stakes in AADI. BlackRock Inc. boosted its stake in shares of Aadi Bioscience by 16.1% during the 2nd quarter. BlackRock Inc. now owns 1,017,124 shares of the company’s stock worth $6,957,000 after acquiring an additional 140,959 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Aadi Bioscience by 11.4% during the 4th quarter. Vanguard Group Inc. now owns 859,697 shares of the company’s stock worth $1,737,000 after acquiring an additional 88,313 shares during the last quarter. State Street Corp boosted its stake in shares of Aadi Bioscience by 72.0% during the 1st quarter. State Street Corp now owns 535,578 shares of the company’s stock worth $9,089,000 after acquiring an additional 224,178 shares during the last quarter. Decheng Capital LLC purchased a new position in shares of Aadi Bioscience during the 4th quarter worth $1,063,000. Finally, Geode Capital Management LLC boosted its stake in shares of Aadi Bioscience by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 332,513 shares of the company’s stock worth $2,274,000 after acquiring an additional 60,814 shares during the last quarter. Institutional investors own 58.31% of the company’s stock.

Aadi Bioscience Company Profile

(Get Free Report)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Further Reading

Insider Buying and Selling by Quarter for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.